Milestone Pharmaceuticals in the spotlight (part III)

Selling MIST position to lock in 30% gains

We previously reported on Milestone Pharma (MIST) here. We bought it just over a month ago under $7/share to play the topline Phase 3 data readout on track for mid-2H 2022. The company has rallied approx. 30% since as more investors piled on the name ahead of the data. We are going to sell the position in $9/share range, before the binary event to lock…